回复:Niven Mehra, Emmanuel S. Antonarakis, Se Hoon Park等。KEYLYNK-010患者报告的结果:派姆单抗联合奥拉帕尼vs阿比特龙或恩杂鲁胺。EurUrol杂志。在出版社。https://doi.org/10.1016/j.euo.2025.04.018。
{"title":"回复:Niven Mehra, Emmanuel S. Antonarakis, Se Hoon Park等。KEYLYNK-010患者报告的结果:派姆单抗联合奥拉帕尼vs阿比特龙或恩杂鲁胺。EurUrol杂志。在出版社。https://doi.org/10.1016/j.euo.2025.04.018。","authors":"Isabel Heidegger","doi":"10.1016/j.euo.2025.07.017","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":9.3000,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Re: Niven Mehra, Emmanuel S. Antonarakis, Se Hoon Park, et al. Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab plus Olaparib Versus Abiraterone or Enzalutamide. EurUrol Oncol. In press. https://doi.org/10.1016/j.euo.2025.04.018.\",\"authors\":\"Isabel Heidegger\",\"doi\":\"10.1016/j.euo.2025.07.017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":12256,\"journal\":{\"name\":\"European urology oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":9.3000,\"publicationDate\":\"2025-10-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European urology oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.euo.2025.07.017\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euo.2025.07.017","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Re: Niven Mehra, Emmanuel S. Antonarakis, Se Hoon Park, et al. Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab plus Olaparib Versus Abiraterone or Enzalutamide. EurUrol Oncol. In press. https://doi.org/10.1016/j.euo.2025.04.018.
期刊介绍:
Journal Name: European Urology Oncology
Affiliation: Official Journal of the European Association of Urology
Focus:
First official publication of the EAU fully devoted to the study of genitourinary malignancies
Aims to deliver high-quality research
Content:
Includes original articles, opinion piece editorials, and invited reviews
Covers clinical, basic, and translational research
Publication Frequency: Six times a year in electronic format